Tysabri (natalizumab) is a prescription drug used for multiple sclerosis (MS), clinically isolated syndrome (CIS), and Crohn’s disease. Tysabri can cause side effects that range from mild to serious.

DUBLIN, April 29 (Reuters) - Elan's Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec said on Wednesday, boosting Elan's ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. When Tysabri first came on the market in 2004 to treat multiple ...

I find it incomprehensible that Melissa Elder, in her review of existing and pending treatments for MS (“Four Therapies Dominate MS Treatment,” October 1, 2007 GEN, pg. 16), simply ignores the ...

Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain ...

Researchers report that they think they have figured out why some patients who take the multiple sclerosis drug Tysabri face a high risk of developing a rare, and sometimes fatal, brain infection. A ...

LONDON (Reuters) - Biogen Idec and Elan have filed for approval to sell their drug Tysabri as a first-line treatment for multiple sclerosis, a move that could boost sales of the drug. Demand for ...

The risk of developing a potentially fatal brain infection is higher than previously thought for patients prescribed a genetically engineered multiple sclerosis drug, scientists said Wednesday. The ...

A drug that was approved for multiple sclerosis patients two years ago but removed from the market because of the risk of brain infections is now back on the market under strict usage guidelines. Dr.

Regulators on both sides of the Atlantic have agreed to review Novartis’ approval bid for a biosimilar to Biogen’s Tysabri. The potential green light could spell trouble for the multiple sclerosis ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. Two drugs generating considerable excitement -- and headlines -- today ...